Comparative Pharmacology
Head-to-head clinical analysis: APHTHASOL versus FLUONID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APHTHASOL versus FLUONID.
APHTHASOL vs FLUONID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aphthasol (amlexanox) is an anti-inflammatory agent that inhibits the formation and release of inflammatory mediators such as histamine and leukotrienes from mast cells, neutrophils, and other inflammatory cells. It also inhibits the activation of eosinophils and neutrophils, and reduces cytokine production, thereby suppressing the immune response involved in aphthous ulcer formation.
Fluocinolone acetonide is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
Adults: 5 mg orally three times daily for 5 days.
0.05% cream or ointment applied topically to affected area once daily. Not to exceed 30 g per week.
None Documented
None Documented
Terminal elimination half-life is 1.5 to 2.5 hours. This short half-life supports multiple daily dosing for local therapeutic effect with minimal systemic accumulation.
3.5 hours; prolonged to 18–24 hours in severe hepatic impairment.
Renal excretion of unchanged drug and metabolites accounts for approximately 50-60% of the administered dose, with the remainder eliminated via biliary/fecal routes as metabolites and unchanged drug. Biliary excretion constitutes about 20-30%.
Renal 70% as unchanged drug, biliary/fecal 30% as metabolites.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid